Deep Track Capital, an investment firm focused exclusively on the life sciences industry, and Forbion, a venture capital firm, led a $175m Series B round in Mariana Oncology, a biotechnology research company focused on pioneering oncology treatment, with participation from Atlas Venture, Access Biotechnology, RA Capital Management, Nextech Invest, Surveyor Capital and Eli Lilly & Company. "The support of such a strong syndicate of new and existing investors is a testament to Mariana Oncology’s potential. In just 18 months since our Series A, we’ve leveraged our deep expertise in peptide discovery and radiochemistry to advance a diversified portfolio of novel molecules. The proceeds from this financing support the advancement of our pipeline and the initial development of our lead candidate, MC-339, which we anticipate will enter the clinic in 2024 in small cell lung cancer, supported by our own GMP radiopharmaceutical manufacturing,” said Simon Read, Mariana Oncology Founder and CEO.